Regulatory bodies like the FDA and EMA often consider interim data when evaluating new cancer treatments. However, they require that the data be robust and derived from well-conducted, scientifically rigorous trials. Regulatory agencies may grant accelerated approval based on interim data, particularly for treatments addressing unmet medical needs.